Anti-tumor activity of new quinoline derivatives in human breast cancer T47D cells

International Journal of Cancer Research

Volumn 2, Issue 2, 2006, Pages 102-108

  Rasoul Amini, Sara ^a   Khalaj, Ali ^a,b   Shafiee, Abbas ^a,b   Daneshtalab, Mohsen ^c   Madadkar Sobhani, Armin ^d   Fouladdel, Shamileh ^b   Azizi, Ebrahim ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Adriamycin; Anti tumor; Azoles; Breast cancer; Quinoline derivatives

Indexed keywords

ANTINEOPLASTIC AGENT; BENZOTHIAZOLE; DOXORUBICIN; ETOPOSIDE; QUINOLINE DERIVATIVE; SRA BQ; SRA HX 1; SRA HX 2; SRA HX 3; TAMOXIFEN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EXPOSURE; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

EID: 33646426113     PISSN: 18119727     EISSN: 18119735     Source Type: Journal    
DOI: 10.3923/ijcr.2006.102.108     Document Type: Article

References (19)

1. Abel, M.D., H.T. Luu, R.G. Micetich, D.Q. Nguyen, M. Nukatsuka, A.B. Oreski, M.L. Tempest and M. Daneshtalab, 1996. Cytotoxic quinolines (Part1). Azolylalkyloxyquinolines and azolylalkyl-4(1H)-quinolines. Drug Des. Discov., 14: 15-30.
2. Abel, M.D., C.M. Ha, H.T. Luu, R.G. Micetich, D.Q. Nguyen, A.B. Oreski, M.L. Tempest and M. Daneshtalab, 1996. Cytotoxic quinolines (Part2). Azolylalkylamino and thioquinolines. Drug Des. Discov., 14: 31-42.
3. Abel, M.D., H.T. Luu, R.G. Micetich, D.Q. Nguyen, A.B. Oreski, M.L. Tempest and M. Daneshtalab, 1996. Synthesis of Azolylalkylquinolines with cytotoxic activity. J. Het. Chem., 33: 415-420.
4. Arancia, G., A. Molinari, A. Calcabrini, S. Meschini and M. Cianfriglia, 2001. Intracellular P-glycoprotein in multidrug resistant tumor cells. Ital. J. Anat. Embryol., 106: 59-68.
5. Callies, S., D.P. de Alwis, J.G. Wright, A. Sandler, M. Burgess and L. Aarons, 2003. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride. Cancer. Chem. Pharmacol., 51: 107-18.
6. Cre, I.A., L. Knight F. Di Nicolantonio, S. Sharma and T. Gulliford, 2002. Hemosensitization of solid tumors by modulation of resistance mechanisms. Curr. Opin. Investig. Drugs, 3: 634-640.
7. Dos Santos Silva, I., P. Mangtani, B.L. De Stavola, J. Bell, M. Quinn and D. Mayer, 2003. Survival from breast cancer among South Asian and non-South Asian women resident in South East England. Br. J. Cancer, 89: 508-512.
8. Dunkern, T.R., I. Wedemeyer, M. Baumgartner, G. Fritz and B. Kaina, 2003. Resistance of p53 knockout cells to doxorubicin is related to reduced formation of DNA strand breaks rather than impaired apoptotic signaling. DNA Repair., 2: 49-60.
9. Engel, J., R. Eckel, J. Kerr, M. Schmidt, G. Furstenberger, R. Richter, H. Saue, H.J. Senn and D. Holzel, 2003. The process of metastasisation for breast cancer. Eur. J. Cancer, 39: 1794-806.
10. Faneyte, I.F., P.M. Kristel and M.J. van de Vijver, 2001. Determining MDR1/P-glycoprotein expression in breast cancer. Intl. J. Cancer, 93: 114-22.
11. Fouladdel, Sh., Z. Motahari and E. Azizi, 2005. Expression of cyclin D1 in Tamoxifen resistant subline of human breast cancer T47D cells. Intl. J. Cancer Res., 1: 16-20.
12. Gewirtz, D.A., 1999. A critical evaluation of the mechanisms of action proposed for the Antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem. Pharmacol., 17: 1311-1318.
13. Larsen, A.K. and A. Skladanowski, 1998. Cellular resistance to topoisomerase-targeted drugs from drug uptake to cell death. Biochim. Biophys. Acta, 1400: 257-274.
14. Li, J., L.Z. Xu, K.L. He, W.J. Guo, Y.H. Zeng, P. Xia and Y. Chen, 2001. Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF-7 breast cancer cell line. Breast Cancer Res., 3: 253-263.
15. Piccart, M., L.M. Parker and K.I. Pritchard, 2003. Oestrogen receptor down regulation: An opportunity for extending the window of endocrine therapy in advanced breast cancer. Am. Oncol., 14: 1017-1025.
16. Schneider, E., J.K. Horton, C.H. Yang, M. Nakagawa and K.H. Cowan, 1994. Multidrug resistance-associated protein gene over expression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF-7 cell line selected for etoposide resistance. Cancer Res., 54: 152-158.
17. Son, Y.S., J.M. Suh, S.H. Ahn, J.C. Kim, J.Y. Yi, K.C. Hur, W.S. Hong, M.T. Muller and I.K. Chung, 1998. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line. Cancer Chem. Pharmacol., 41: 353-360.
18. Uchiyama-Kokubu, N. and T. Watanabe, 2001. Establishment and characterization of adriamycin-resistant human colorectal adenocarcinoma HCT-15 cell lines with multidrug resistance. Anticancer Drugs, 12: 769-79.
19. Whelan, R.D., C.J. Waring and J.D. Hayes, 1992. Overexpression of P-glycoprotein and glutathione S-transferase in MCF-7 cells selected for vincristin resistance in vitro. Intl. J. Cancer, 52: 241-246.